With Type 1 Diabetes Delay Possible, Now Focus on Screening
The recent approval of teplizumab-mzwv (Tzield, Provention Bio) for delaying type 1 diabetes by the U.S. Food and Drug Administration should advance efforts to increase screening to cost-effectively identify people at risk of the disease who would be eligible to receive the new treatment. The anti-CD3 monoclonal antibody was approved on November 17 as the …
With Type 1 Diabetes Delay Possible, Now Focus on Screening Read More »